|1.||Bhat, Hari K: 2 articles (07/2009 - 01/2004)|
|2.||Di Giulio, Richard T: 2 articles (12/2007 - 12/2004)|
|3.||Rider, Barbara: 1 article (06/2015)|
|4.||Mondal, Debasis: 1 article (06/2015)|
|5.||Ranjan, Manish: 1 article (06/2015)|
|6.||Datta, Amrita: 1 article (06/2015)|
|7.||Abdel-Mageed, Asim B: 1 article (06/2015)|
|8.||Bhasin, Nobel: 1 article (06/2015)|
|9.||Agrawal, Krishna C: 1 article (06/2015)|
|10.||Kim, Hogyoung: 1 article (06/2015)|
09/01/1991 - "Syrian hamsters were treated with ethinylestradiol and maintained on a diet containing alpha-naphthoflavone (alpha NF), a regimen that produces a high incidence of liver tumors. "
01/01/1990 - "Modification of 7,8-benzoflavone metabolism in hamster liver and kidney microsomes by hepatic tumor inducing treatments."
07/01/1983 - "7,8-Benzoflavone, at a 367-nmol dose, did not inhibit tumor promotion by BrMBA. "
01/01/2004 - "Tumor cells were also treated with alpha-naphthoflavone, a cytochrome P450 inhibitor, or a combination of alpha-naphthoflavone and E2 to study the effect of metabolic activation of E2 on E2-induced oxidative stress. "
09/01/1991 - "Comparative morphologic and immunohistochemical studies of estrogen plus alpha-naphthoflavone-induced liver tumors in Syrian hamsters and rats."
|2.||Congenital Abnormalities (Deformity)
12/01/2004 - "In agreement with previous studies, coexposure of embryos to PCB-126 with the AHR antagonist and CYP1A inhibitor alpha-naphthoflavone decreased frequency and severity of deformities compared with embryos exposed to PCB-126 alone. "
12/30/2007 - "In this study, we further examined this interaction of the model PAH and AHR agonist beta-naphthoflavone (BNF) with and without the AHR partial agonist/antagonist and CYP1A inhibitor alpha-naphthoflavone (ANF) to determine (1) whether ANF was acting as an AHR antagonist, (2) what alterations BNF and ANF both alone and in combination had on mRNA expression of the AHR regulated genes cytochrome P450 (cyp) 1a, 1 b 1, and 1 c 1, and the AHR repressor (ahrr2) prior to versus during deformity onset, and (3) compare CYP1A enzyme activity with mRNA induction. "
|3.||Hepatocellular Carcinoma (Hepatoma)
05/15/1998 - "Induction in wild-type hepatoma cells was antagonized effectively by a molar excess of alpha-naphthoflavone. "
08/01/1984 - "High incidence of hepatocellular carcinomas after synthetic estrogen administration in Syrian golden hamsters fed alpha-naphthoflavone: a new tumor model."
08/01/1999 - "The AHR-containing murine hepatoma cell line 1c1c7 arrested following exposure to AHR agonist concentrations of flavone and alpha-naphthoflavone, but not TCDD. "
10/01/1993 - "In contrast, with other partial Ah receptor antagonists such as alpha-naphthoflavone, cotreatment of rat hepatoma H4II E cells with 1 nM TCDD plus 1 and 10 microM 6-t-butyl-3,4-benzocoumarin did not result in decreased levels of the Ah receptor complex (liganded with TCDD). "
08/01/1984 - "P8 80-100% incidence of multinodular hepatocellular carcinomas was observed in castrated male hamsters following synthetic estrogen treatment in the presence of 0.2-0.4% alpha-naphthoflavone (ANF) in the diet after 8.5-10 months. "
|4.||Breast Neoplasms (Breast Cancer)
10/01/2008 - "The flavonoid 7,8-benzoflavone was recently identified as one of the most potent inhibitors of breast cancer resistance protein (BCRP); however, little is known of the in vivo disposition of 7,8-benzoflavone. "
06/28/2015 - "Selective targeting of FAK-Pyk2 axis by alpha-naphthoflavone abrogates doxorubicin resistance in breast cancer cells."
06/01/1993 - "Mechanism of action of alpha-naphthoflavone as an Ah receptor antagonist in MCF-7 human breast cancer cells."
01/01/2002 - "These effects are counteracted by the AhR-antagonist alpha-naphthoflavone (ANF), and in breast cancer cells expressing mutant p53 or the E6 human papilloma virus protein. "
07/01/1981 - "Injection of 80 mg beta-naphthoflavone per kg into tumor-bearing C3H/HeJ mice or Sprague-Dawley rats increased AHH activity to 10- to 70-fold over basal levels; there was no significant AHH induction in tumors from genetically "nonresponsive" DBA/2J or RF/J mice treated with beta-naphthoflavone, alpha-Naphthoflavone in the incubation flask inhibited AHH activity in some human breast tumors and stimulated activity in others, probably reflecting the presence of multiple forms of cytochrome(s) P-450 in the human tumor population. "
|5.||Chromosome Aberrations (Chromosome Abnormalities)
01/01/1988 - "Peripheral lymphocytes from Taiwanese women (n = 35) exposed to polychlorinated aromatic hydrocarbons and from matched controls (n = 24) were assessed for the levels of sister chromatid exchanges (SCEs) after a 72-hour incubation of whole blood in the presence or absence of alpha-naphthoflavone (ANF) and for chromosome aberrations after 48 hours of incubation. "
04/01/2000 - "The incidence of chromosome aberrations was not affected by co-treatment with alpha-naphthoflavone, an inhibitor of 2-hydroxylase that inhibits oxidative conversion of 2-MeOE(2) to 2-hydroxyestradiol, but the incidence was slightly increased by co-treatment with L-ascorbic acid. "
|1.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|2.||Atrial Natriuretic Factor (ANF)
|5.||Messenger RNA (mRNA)
|10.||Cytochrome P-450 CYP1A1 (CYP1A1)